Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Arcturus Therapeutics Ltd (ARCT)

Arcturus Therapeutics Ltd (ARCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 436,605
  • Shares Outstanding, K 26,493
  • Annual Sales, $ 12,360 K
  • Annual Income, $ -203,670 K
  • 60-Month Beta 2.51
  • Price/Sales 35.10
  • Price/Cash Flow N/A
  • Price/Book 3.00
Trade ARCT with:

Options Overview Details

View History
  • Implied Volatility 85.01% ( +4.86%)
  • Historical Volatility 91.55%
  • IV Percentile 2%
  • IV Rank 6.03%
  • IV High 160.80% on 08/01/22
  • IV Low 80.15% on 11/25/22
  • Put/Call Vol Ratio 4.64
  • Today's Volume 62
  • Volume Avg (30-Day) 573
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 8,481
  • Open Int (30-Day) 9,796

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 3.00
  • Number of Estimates 3
  • High Estimate 5.44
  • Low Estimate -1.86
  • Prior Year -1.47
  • Growth Rate Est. (year over year) +304.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.55 +3.47%
on 11/22/22
24.65 -34.73%
on 11/02/22
-1.27 (-7.32%)
since 10/28/22
3-Month
13.02 +23.58%
on 09/26/22
24.65 -34.73%
on 11/02/22
+1.08 (+7.20%)
since 08/26/22
52-Week
11.70 +37.52%
on 06/16/22
48.75 -66.99%
on 12/20/21
-23.80 (-59.66%)
since 11/26/21

Most Recent Stories

More News
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

ARCT : 16.09 (-2.37%)
ETON : 2.90 (-3.01%)
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development...

ARCT : 16.09 (-2.37%)
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the...

SRRK : 7.51 (-5.30%)
ARCT : 16.09 (-2.37%)
Arcturus Therapeutics to Present at the Following Investor Conferences in November

Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 16.09 (-2.37%)
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

ARCT : 16.09 (-2.37%)
ADCT : 3.40 (-5.29%)
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -12.86% and 41.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

KYMR : 27.33 (-1.58%)
ARCT : 16.09 (-2.37%)
Why Arcturus Therapeutics Stock Is Skyrocketing Today

Investors are applauding Arcturus' collaboration with CSL.

CSL.AX : 301.770 (+0.48%)
CSLLY : 100.1200 (-0.95%)
ARCT : 16.09 (-2.37%)
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 16.09 (-2.37%)
CSL : 257.25 (-0.41%)
CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

/PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement...

ARCT : 16.09 (-2.37%)
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q3 Earnings and Revenue Estimates

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 850% and 3.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for...

HRMY : 57.89 (-0.34%)
ARCT : 16.09 (-2.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as...

See More

Key Turning Points

3rd Resistance Point 17.15
2nd Resistance Point 16.90
1st Resistance Point 16.50
Last Price 16.09
1st Support Level 15.84
2nd Support Level 15.59
3rd Support Level 15.19

See More

52-Week High 48.75
Fibonacci 61.8% 34.60
Fibonacci 50% 30.23
Fibonacci 38.2% 25.85
Last Price 16.09
52-Week Low 11.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar